Product Development Catalysts To Look Out For This Quarter
This article was originally published in Scrip
The last quarter of this year will see major catalyst events for around 20 drugs, latest research from Sagient's BioMedTracker shows. Big pharma companies expecting data read-outs or regulatory action before Christmas include both Mercks, AstraZeneca and AbbVie, while advances are expected for three treatments for pancreatic cancer and two novel antibiotics, among others.
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.